MARKET

RIGL

RIGL

Rigel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.030
-0.010
-0.49%
After Hours: 2.010 -0.02 -0.99% 16:28 05/28 EDT
OPEN
2.080
PREV CLOSE
2.040
HIGH
2.100
LOW
2.000
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
3.100
52 WEEK LOW
1.230
MARKET CAP
342.20M
P/E (TTM)
-12.0546
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RIGL stock price target is 7.17 with a high estimate of 8.00 and a low estimate of 5.00.

EPS

RIGL News

More
JP Morgan Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to $6
JP Morgan maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Overweight and lowers the price target from $7 to $6.
Benzinga · 1d ago
Rigel to Present at the Jefferies Virtual Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.
PR Newswire · 2d ago
Rigel Pharmaceuticals Remains Undervalued Despite Slowdown In Q1 Tavalisse Sales
Seeking Alpha - Article · 05/13 03:43
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St. · 05/08 16:03
Edited Transcript of RIGL earnings conference call or presentation 5-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/06 10:24
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/06 04:21
Rigel Pharmaceuticals (RIGL) Q1 Earnings Match Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:15
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
PR Newswire · 05/05 21:01

Industry

Biotechnology & Medical Research
+0.35%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About RIGL

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
More

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.